MedTrace Logo

MCLA-117 in Acute Myelogenous Leukemia

NCT03038230 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-04-06

No results posted yet for this study

Summary

This is a First-in-Human, single arm, open-label, multi-national study designed to determine the safety, tolerability and preliminary efficacy of MCLA 117.

Conditions

Interventions

DRUG

MCLA-117 bispecific antibody

MCLA-117, a human bispecific IgG antibody which targets CLEC12A and CD3

Sponsors & Collaborators

  • Merus N.V.

    lead INDUSTRY

Principal Investigators

  • Jorge Cortes, MD, PhD · Independent Protocol Advisor

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2021-05-11
Completion
2021-05-11

Countries

  • United States
  • Belgium
  • France
  • Italy
  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03038230 on ClinicalTrials.gov